- Home
- DXR vs ESLA Comparison
DXR vs ESLA Comparison
Compare DXR & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- ESLA
- Stock Information
- Founded
- DXR 1970
- ESLA 2021
- Country
- DXR United States
- ESLA United States
- Employees
- DXR N/A
- ESLA N/A
- Industry
- DXR Medical/Dental Instruments
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXR Health Care
- ESLA Health Care
- Exchange
- DXR Nasdaq
- ESLA Nasdaq
- Market Cap
- DXR 36.4M
- ESLA 35.5M
- IPO Year
- DXR N/A
- ESLA N/A
- Fundamental
- Price
- DXR $9.75
- ESLA $0.85
- Analyst Decision
- DXR Strong Buy
- ESLA Strong Buy
- Analyst Count
- DXR 1
- ESLA 1
- Target Price
- DXR $25.00
- ESLA $16.00
- AVG Volume (30 Days)
- DXR 5.6K
- ESLA 522.0K
- Earning Date
- DXR 01-01-0001
- ESLA 08-20-2025
- Dividend Yield
- DXR N/A
- ESLA N/A
- EPS Growth
- DXR 86.16
- ESLA N/A
- EPS
- DXR 0.11
- ESLA N/A
- Revenue
- DXR $119,714.00
- ESLA N/A
- Revenue This Year
- DXR N/A
- ESLA $101.09
- Revenue Next Year
- DXR N/A
- ESLA N/A
- P/E Ratio
- DXR $84.18
- ESLA N/A
- Revenue Growth
- DXR N/A
- ESLA N/A
- 52 Week Low
- DXR $6.55
- ESLA $0.63
- 52 Week High
- DXR $10.00
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- DXR 69.88
- ESLA 46.99
- Support Level
- DXR $8.68
- ESLA $0.89
- Resistance Level
- DXR $9.03
- ESLA $1.02
- Average True Range (ATR)
- DXR 0.47
- ESLA 0.09
- MACD
- DXR 0.03
- ESLA -0.00
- Stochastic Oscillator
- DXR 90.38
- ESLA 21.16
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.